Techno Medica (6678) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2024, increased 1.5% year-over-year to ¥4,116.96 million, driven by overseas equipment sales and steady demand for consumables.

• Operating profit declined 41.8% year-over-year to ¥304.80 million due to higher R&D and personnel costs.

• Net profit fell 41.1% year-over-year to ¥221.85 million.

• Overseas sales ratio rose 3.9 points to 17.1% of total revenue.

Financial highlights

• Gross profit was ¥2,078.53 million, up 0.8% year-over-year.

• SG&A expenses increased 15.4% year-over-year to ¥1,773.73 million.

• Ordinary profit dropped 44.0% year-over-year to ¥298.58 million.

• EPS for the period was ¥32.06, down from ¥46.16 in the prior year.

Outlook and guidance

• Full-year revenue forecast remains unchanged at ¥10,000 million, a 2.8% decrease from the previous year.

• Full-year operating profit forecast is ¥1,400 million, down 23.9% year-over-year.

• Net profit for the year is projected at ¥970 million, a 28.0% decrease year-over-year.

• Annual dividend forecast is ¥68 per share, unchanged from the previous year.